Testolactone_药物分子靶点数据库

来自 : 药智数据 发布时间：2021-03-24

Although the precise mechanism by which testolactone produces its clinical antineoplastic effects has not been established, its principal action is reported to be inhibition of steroid aromatase activity and consequent reduction in estrone synthesis from adrenal androstenedione, the major source of estrogen in postmenopausal women. Based on in vitro studies, the aromatase inhibition may be noncompetitive and irreversible. This phenomenon may account for the persistence of testolactone\'s effect on estrogen synthesis after drug withdrawal.
药品名称 Testolactone 分子靶点 Cytochrome P450 19A1 药物类型 Small Molecule 研发阶段 Approved, Investigational 药物描述 An antineoplastic agent that is ...Testolactone,分子靶点,药物靶点TestolactoneTestolactone